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Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily 
pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% 
treated patients achieve disease stabilisation or better at the first radiological evaluation. In addition 
to that a particularly broad spectrum of toxicities (experienced as G3 or more NCI CTCAE graded by 
50% of patients treated) have led to reconsider its widespread use in the majority of patients. We 
retrospectively collected data about the magnitude of off-target effects experienced during the first 
8-weeks of regorafenib monotherapy and analysed their correlation with overall survival, progression 
free survival and disease control rate. Our findings suggest that skin rash (Exp (B): 0.52, p = 0.0133) or 
hypothyroidism (Exp (B): 0.11, p = 0.0349) were significantly correlated with improved overall survival 
at multivariate regression analysis. It was also demonstrated a statistically significant role of diarrhea as 
predictor of improved survival but its independent prognostic role was lost at multivariate analysis (Exp 
(B): 0.63, p = 0.162). This is the first analysis showing a potential correlation between the onset of these 
forms of side effects and regorafenib efficacy, however sample size limitations and the retrospective 
nature of our analysis prevent us from drawing definitive conclusions.
Regorafenib represents a relevant treatment opportunity for patients with metastatic colorectal cancer (mCRC) 
failing previous therapy with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, anti-VEGF ther-
apy and, if RAS wild type, anti-EGFR therapy1–5. The most common adverse effects observed with the use of 
regorafenib include hand and foot skin reaction (HFSR) (17%), skin rash (6%), fatigue (10%), diarrhoea (7%) and 
hypertension (7%)2.
Some of these adverse reactions, although not fatal, can be debilitating causing both physical and emotional 
discomfort6. In addition, not all subgroups of patients seem to benefit from treatment with regorafenib and there-
fore a non-negligible proportion of patients are exposed to unnecessary toxicity without deriving any clinical 
advantage. Many clinical and biological variables have been analysed in order to better identify patients more 
likely to achieve an improved clinical outcome from this treatment. Unfortunately, to date, no predictive marker 
has been validated for the clinical practice7–10. An interesting area of research in this setting is also represented 
by the potential role of off-target effects of different targeted agents to affect clinical outcome. In patients diag-
nosed with different tumour types receiving oral multikinase inhibitors with a pharmacological profile partially 
overlapping regorafenib (e.g. sunitinib, sorafenib, pazopanib) off-target adverse effects have been analysed as 
possible early markers of response and clinical benefit. In advanced hepatocellular carcinoma patients receiving 
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sorafenib the occurrence of early HFSR correlated in fact with a prolonged time to progression (TTP) and an 
improved overall survival (OS)11–13. Similarly, arterial hypertension has been correlated with improved OS during 
treatment with sorafenib, sunitinib and pazopanib in different malignancies14. Sorafenib-induced diarrhoea has 
been associated with improved OS15. In this view also thyroid dysfunction has been evaluated in patients treated 
with sunitinib. In renal cell carcinoma patients receiving sunitinib the development of antithyroid peroxidase 
(TPOAb) autoantibodies along with severe hypothyroidism was associated with a longer progression free survival 
(PFS)16. In the TRIBUTE (Toxicity during Regorafenib Induction and Benefit Under Treatment Extension) anal-
ysis we evaluated the potential role of off target effects as early surrogate markers of clinical outcome in patients 
with colorectal cancer treated with regorafenib with the final aim to improve the early identification of patients 
more likely to benefit from such a treatment approach and optimise adverse events management.
Results
A total number of 144 patients were included in our analysis. In the global population 9 (6%) patients achieved 
partial response, 37 (26%) patients had stable disease at their first radiological evaluation. Eighty-six (60%) 
patients progressed under treatment. In 12 (8%) patients radiological evaluation of response was not performed 
(Table 1). Median progression free survival was 2.8 months (95%CI: 2.557–3.148) and median overall survival 
was 6 months (95%CI: 4.0–9.213). One hundred and twenty-four patients (86%) had already progressed and 89 
patients (62%) had already died at the time of analysis. Forty-one patients (28%) showed HFSR, 21 patients (15%) 
had diarrhea, 29 patients (20%) had hypertension, 38 patients (26%) had skin rash, 65 patients (45%) had fatigue, 
18 patients (12%) had increased AST/ALT, 15 patients (10%) had increased bilirubin, 13 patients (9%) showed 
hypothyroidism.
Off-target effects and Clinical Outcome. HFSR. Disease control rate (DCR) for patients with grade 
≥ 2 HFSR was 47% vs 25% for the remaining patients. This difference was statistically significant (p = 0.0269). 
Median PFS for patients with grade ≥ 2 HFSR vs the remaining patients was 3.2 vs 2.5 months (HR: 0.73, 95%CI: 
Total (%)
SEX
Male 82 (57)
Female 62 (43)
Age
Median (Range) 62 (32–80)
< 70 y.o 123 (86)
≥ 70 y.o 21 (14)
RAS status
WT 58 (40)
MUT 86 (60)
Previous anti-EGFR treatment 58 (40)
Previous anti-VEGF treatment 144 (100)
Previous lines of treatment
2 60 (41)
3 62 (43)
4 or more 22 (16)
ECOG PS at treatment start
0 103 (72)
≥ 1 41 (28)
19
Baseline Blood Pressure
Normal pressure 62 (43)
Pre-existing hypertension managed by therapy 82 (57)
Median OS 6 months
Median PFS 2.8 months
Response Rate
PR 9 (7.3)
SD 37 (27)
PD 86 (60)
NE 12 (8)
Table 1.  Main patients’ characteristics in the overall study population. WT = wild type. MUT = mutant. 
EGFR = Epidermal Growth Factor Receptor. VEGF = Vascular Endothelial Growth Factor. ECOG PS = Overall 
Survival. OS = Overall Survival. PFS = Progression-Free Survival. PR = Partial Remission. SD = Stable Disease. 
PD = Progressive Disease. NE = Not Evaluated.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:45703 | DOI: 10.1038/srep45703
0.51–1.04, p = 0.10), respectively. (Figure 1). Median OS for patients with grade ≥ 2 HFSR vs the remaining 
patients was 6.59 vs 5.96 months (HR: 0.80, 95%CI: 0.52–1.25, p = 0.35), respectively. (Figure 1) (Table 2).
Skin Rash. DCR for patients showing skin rash grade ≥ 2 was 55% vs 21% for the remaining patients. This differ-
ence was statistically significant (p = 0.000387). Median PFS for patients with grade ≥ 2 skin rash vs the remaining 
patients was 3.67 vs 2.68 months (HR: 0.60, 95%CI: 0.42–0.86, p = 0.0096), respectively. (Figure 2). Median OS for 
patients with grade ≥ 2 skin rash vs the remaining patients was 10.36 vs 5.04 months (HR: 0.54, 95%CI: 0.36–0.84, 
p = 0.0085), respectively. (Figure 2) (Table 2).
Hypertension. DCR was 48% vs 27% (p = 0.0526), respectively, for patients showing grade ≥ 2 hypertension vs 
the remaining patients. Median PFS for patients who developed grade ≥ 2 hypertension was 4.32 months vs 2.65 
months for the remaining patients (HR: 0.61, 95%CI: 0.41–0.89, p = 0.0197) (Fig. 3).
Median OS for patients who developed grade ≥ 2 hypertension vs those who did not was 7.18 vs 5.04 months 
(HR: 0.71, 95% CI: 0.45–1.13, p = 0.188), respectively. (Figure 3) (Table 2).
Diarrhea. DCR was 53% vs 27% (p = 0.0489), respectively, for patients experiencing grade ≥ 2 diarrhea vs the 
remaining patients. Median PFS for patients who experienced grade ≥ 2 diarrhea was 5.11 vs 2.65 months for the 
remaining patients (HR: 0.54, 95%CI: 0.36–0.81, p = 0.0130). (Figure 4). Median OS for patients who experienced 
grade ≥ 2 diarrhea was 11.41 vs 5.27 months for the remaining patients (HR: 0.53, 95%CI: 0.32–0.88, p = 0.0440). 
(Figure 4) (Table 2).
Hypothyroidism. DCR for patients showing grade ≥ 2 hypothyroidism vs the remaining patients was 71% vs 
28% (p = 0.03), respectively. Median PFS for patients who experienced grade ≥ 2 hypothyroidism was 7.96 vs 2.75 
months for the remaining patients (HR: 0.56, 95%CI: 0.34–0.93, p = 0.0635) (Fig. 5).
Median OS for patients showing grade ≥ 2 hypothyroidism was not reached vs 5.83 months for the remaining 
patients (HR: 0.10, 95%CI: 0.05–0.19, p = 0.0042) (Fig. 5) (Table 2).
Fatigue. DCR was 32% vs 30% (p = 1.0), respectively, for patients experiencing grade ≥ 2 fatigue vs the remain-
ing patients. Median PFS for patients who developed grade ≥ 2 fatigue vs the remaining patients was 2.85 vs 2.68 
months (HR: 0.93, 95%CI: 0.66–1.32, p = 0.716), respectively. Median OS was also not significantly different 
between the two groups of patients, with median OS 7.18 vs 6.03 months, respectively, for patients who developed 
grade ≥ 2 fatigue vs the remaining patients (HR: 0.76, 95%CI: 0.50–1.14, p = 0.195) (Table 2).
AST/ALT increase. DCR was 43% vs 29% (p = 0.22), respectively, for patients showing grade ≥ 2 AST/ALT 
increase vs the remaining patients. Median PFS for patients showing grade ≥ 2 AST/ALT increase vs the remain-
ing patients was 3.01 vs 2.78 months (HR: 1.11, 95%CI: 0.65–1.89, p = 0.68), respectively.
Median OS for patients who experienced grade ≥ 2 AST/ALT increase vs the remaining patients was 4.13 vs 
6.32 months (HR: 1.60, 95%CI: 0.83–3.10, p = 0.08), respectively (Table 2).
Bilirubin increase. DCR was 23% vs 32% (p = 0.75), respectively, for patients showing grade ≥ 2 bilirubin 
increase vs the remaining patients. Median PFS for patients showing grade ≥ 2 bilirubin increase vs the remain-
ing patients was 2.82 vs 2.78 months (HR: 1.42, 95%CI: 0.75–2.69, p = 0.20), respectively. Median OS was not 
Figure 1. Median PFS (a) and OS (b) for patients who developed ≥ grade 2 HFSR ( ) vs patients with 
grade 0–1 HFSR ( ). Median PFS was 3.27 vs 2.52 months (HR: 0.73, 95%CI: 0.51–1.04, p = 0.10), 
respectively, whereas median OS was 6.59 vs 5.96 months (HR: 0.80, 95%CI: 0.52–1.25, p = 0.35), respectively.
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significantly worse in patients showing grade ≥ 2 bilirubin increase vs the remaining patients (8.98 vs 6.03 
months, HR: 1.21, 95%CI: 0.63–2.33, p = 0.52, respectively) (Table 2).
Other tested variables. ECOG PS. Forty-one patients (28%) showed an ECOG ≥ 1 whereas the remain-
ing 103 patients (72%) were ECOG 0. DCR in ECOG 0 vs ECOG ≥ 1 was 29% vs 17% (p = 0.10), respectively. No 
statistically significant differences were observed for PFS and OS. In particular, median PFS for ECOG 0 vs ECOG 
≥ 1 patients was 3.01 vs 2.69 months (HR: 0.88, 95%CI: 0.60–1.30, p = 0.52), respectively, whereas median OS for 
ECOG 0 vs ECOG ≥ 1 was 6.75 vs 6.16 months (HR: 0.70, 95%CI: 0.44–1.10, p = 0.10), respectively.
Gender. Eighty-two (57%) patients were male whereas the remaining 62 (43%) were female. DCR was 30% vs 
9% for male vs female patients (p = 0.17), respectively. Median PFS for male vs female patients was 3.01 vs 2.65 
months, HR: 0.77, 95%CI: 0.54–1.10, p = 0.13), respectively. Median OS for male vs female patients was 7.67 vs 
5.27 months (HR: 0.81, 95%CI: 0.53–1.23, p = 0.31), respectively.
Age. Patients’ median age was 62 (range 32–80). Age (< 70 vs ≥ 70 years) did not have a statistically significant 
impact on patients’ clinical outcome. Twenty-one patients (14%) were ≥ 70 years old whereas the remaining 123 
(86%) were < 70 years old. DCR in the < 70 vs ≥ 70 years old groups was 28 and 14% (p = 0.28), respectively. 
Median PFS was 2.88 vs 2.29 months (HR: 1.06, 95%CI: 0.55–2.03, p = 0.85), respectively, for < 70 vs ≥ 70 years 
old patients. Median OS was 5.83 vs 4.45 months (HR: 0.81, 95%CI: 0.37–1.75, p = 0.62), respectively, for < 70 vs 
≥ 70 years old patients.
RAS mutational status. Eighty-six (60%) patients were RAS mutant whereas the remaining 58 (40%) were RAS 
WT. We did not observe any significant differences in terms of DCR, OS and PFS between RAS WT patients 
vs RAS mutant.DCR was 34% for RAS WT patients while DCR was 20% for RAS mutant patients (p = 0.053), 
respectively. Median PFS for RAS WT patients vs RAS mutant was 2.85 vs 2.78 months (HR: 0.86,95%CI: 0.54–
1.35, p = 0.50), respectively. Median OS for RAS WT patients vs RAS mutant was 5.54 vs 6.45 months (HR: 1.06, 
95%CI: 0.64–1.73, p = 0.81), respectively.
Regorafenib dose at the time of progression. At the time of disease progression 57 patients (40%) were on full dose 
regorafenib (160 mg/day), 67 patients (46%) were on 120 mg/day regorafenib and the remaining 18 patients (12%) 
were receiving regorafenib 80 mg/day. Median PFS for 160 mg/day, 120 mg/day and 80 mg/day cohorts was 2.85, 
DCR p PFS (months) HR (95% CI) p OS (months) HR (95% CI) p
HFSR
Grade ≥ 2: 41 (28%) 47%
0.0269
3.2
0.73 (0.51–1.04) 0.10
6.59
0.80 (0.52–1.25) 0.35
Grade 0–1: 103 (72%) 25% 2.5 5.96
SKIN RASH
Grade ≥ 2: 38 (26%) 55%
0.00387
3.67
0.60 (0.42–0.86) 0.0096
10.36
0.54 (0.36–0.86) 0.0085
Grade 0–1: 106 (74%) 21% 2.68 5.04
HYPERTENSION
Grade ≥ 2: 29 (20%) 48%
0.0526
4.32
0.61 (0.41–0.89) 0.0197
7.18
0.71 (0.45–1.13) 0.188
Grade 0–1: 115 (80%) 27% 2.65 5.04
FATIGUE Yes/No
Grade ≥ 2: 65 (45%) 32%
1.0000
2.85
0.93 (0.66–1.32) 0.716
7.18
0.76 (0.50–1.14) 0.195
Grade 0–1: 79 (55%) 30% 2.68 6.03
AST/ALT ELEVATION
Grade ≥ 2: 18 (12%) 43%
0.29
3.01
1.11 (0.65–1.89) 0.68
4.16
1.60 (0.83–3.10) 0.08
Grade 0–1: 126 (88%) 29% 2.78 6.32
BILIRUBIN INCREASE
Grade ≥ 2: 15 (10%) 23%
0.75
2.82
1.42 (0.75–2.69) 0.20
8.98
1.21 (0.63–2.33) 0.52
Grade 0–1: 129 (90%) 32% 2.78 6.03
HYPOTHYROIDISM
Grade ≥ 2: 13 (9%) 71%
0.03
7.96
0.56 (0.34–0.93) 0.0635
NR
0.10 (0.05–0.19) 0.0042
Grade 0–1: 131 (91%) 28% 2.75 5.83
DIARRHEA
Grade ≥ 2: 21 (15%) 53%
0.0489
5.11
0.54 (0.36–0.81) 0.0130
11.41
0.53 (0.32–0.88) 0.0440
Grade 0-1: 123 (85%) 27% 2.65 5.27
Table 2.  Results of univariate analysis for different regorafenib-related off-target effects on patients’ 
outcome in terms of DCR, mPFS and mOS. DCR = disease control rate, PFS = progression-free survival, 
HR = Hazard ratio, CI = confidence interval, OS = overall survival, HFSR = hand and foot skin reaction, 
AST = Aspartate Aminotransferase, ALT = alanine aminotransferase.
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2.95 and 3.14 months (p = 0.39), respectively. Median OS for 160 mg/day, 120 mg/day and 80 mg/day cohorts was 
5.13, 6.27 and 5.27 months (p = 0.62), respectively.
Multivariate analysis results. Multivariate analysis for PFS was performed by including in the model only 
those variables who were correlated with a stratistically significant impact on PFS in univariate analysis, namely 
skin rash development, hypertension and diarrhea.
All these factors maintained their independent roles as predictors of different PFS, respectively skin rash 
(cox-regression exponential [Exp (B)]: 0.59, p = 0.0112), hypertension (Exp (B): 0.57, p = 0.0115) and diarrhea 
(Exp (B): 0.47, p = 0.0042).
Multivariate analysis for OS was performed by including only those variables that resulted to be correlated 
with a significantly different OS at univariate analysis, namely skin rash, diarrhea, hypothyroidism At multivar-
iate analysis for OS only skin rash (Exp (B): 0.52, p = 0.0133) and hypothyroidism (Exp (B): 0.11, p = 0.0349) 
Figure 2. Median PFS (a) and OS (b) for patients who developed ≥ grade 2 skin rash ( ) vs patients with 
grade 0–1 skin rash ( ). Median PFS was 3.67 vs 2.68 months (HR: 0.60, 95%CI: 0.42–0.86, p = 0.0096), 
respectively, whereas median OS was 10.36 vs 5.04 months (HR: 0.54, 95%CI: 0.36–0.84, p = 0.0085), 
respectively.
Figure 3. Median PFS (a) and OS (b) for patients who developed ≥ grade 2 hypertension ( ) vs patients 
with grade 0–1 hypertension ( ). Median PFS was 4.32 vs 2.65 months (HR: 0.61, 95%CI: 0.41–0.89, 
p = 0.0197), respectively, whereas median OS was 7.18 vs 5.04 months (HR: 0.71, 95%CI: 0.45–1.13, p = 0.188), 
respectively.
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maintained their independent role whereas diarrhea (Exp (B): 0.63, p = 0.162) lost its role as independent pre-
dictor of different OS.
On the basis of the independent prognostic roles of each single toxicity identified as potential indicator of 
different PFS or OS, looking closely at patients who had more than one side-effects, a cumulative effect could 
be seen: in particular, when we looked at the PFS for patients who experienced all 3 side-effects (4/144, 3%) 
compared with those patients who just experienced 2 side-effects (25/144, 17%) or those with only 1 side-effect 
(39/144, 27%), a strikingly improved PFS was seen with each additional side-effect (HR for PFS respectively 0.36 
for 3 side-effects vs none, 0.40 for 2 side-effects vs none, 0.48 for only 1 side-effects vs none, Fig. 6).
Discussion
Since its introduction in 2013, fine-tuning of regorafenib-based therapy has always been a challenging issue. 
If on the one hand regorafenib is in fact able to improve the therapeutic possibilities for pre-treated metastatic 
Figure 4. Median PFS (a) and OS (b) for patients who developed ≥ grade 2 diarrhea ( ) vs patients with 
grade 0–1 diarrhea ( ). Median PFS was 5.11 vs 2.65 months (HR: 0.54, 95%CI:  
0.36–0.81, p = 0.0130), respectively, whereas median OS was 11.41 vs 5.27 months (HR: 0.53, 95%CI: 0.32–0.88, 
p = 0.0440), respectively.
Figure 5. Median PFS (a) and OS (b) for patients who developed ≥ grade 2 hypothyroidism ( ) vs patients 
with grade 0–1 hypothyroidism ( ). Median PFS was 7.96 vs 2.75 months (HR: 0.56, 95%CI: 0.34–0.93, 
p = 0.0635), respectively, whereas median OS was 7.96 vs 2.75 months (HR: 0.56, 95%CI: 0.34–0.93, p = 0.0635), 
respectively.
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colorectal cancer patients, on the other hand a non-negligible proportion of patients are exposed to toxicity with-
out deriving any clinical benefit. Patients enrolled in the CORRECT and CONCUR2,3 trials have experienced as 
much as a 50% risk of severe (G3 NCI CTCAE or more) toxicity and an even more increased risk of less severe 
combined toxicities. Nonetheless, recent observational studies such as the CONSIGN and REBECCA trials4,5 
have suggested that efficacy results are also reproducible in patients treated outside the setting of a randomised 
clinical trial. Unfortunately, along with the efficacy profile the toxicity profile was also unchanged and difficult 
to manage. The proper management of adverse events then becomes a relevant issue, particularly if we consider 
that as many as 50% of patients are not expected to benefit from this drug and that most patients are more likely 
to experience disease stabilisation, rather than a typical objective response. Several Authors have suggested a 
correlation between toxicity (off-target effects) and clinical outcome in different tumours types treated with dif-
ferent anti-neoplastic agents. We previously demonstrated a possible link between hypertension and clinical out-
come for patients treated with first-line FOLFIRI and the anti-angiogenic monoclonal antibody bevacizumab17. 
Subsequently other Authors18,19 confirmed the correlation between increased arterial blood pressure during bev-
acizumab therapy and clinical outcome for patients with metastatic colorectal cancer. This correlation was also 
evident in other cancer types, such as metastatic breast cancer20. Similarly, in the present analysis hypertension 
was able to influence progression free survival, however this did not translate into an independent role for overall 
survival thus suggesting that hypertension might not be as relevant as other factors when a multi tyrosine kinase 
inhibitor, such as regorafenib, is used. Due to the broad range of pharmacological activity, regorafenib may induce 
skin-based toxicities such as skin rash or the more common hand-foot skin reaction. These peculiar toxicities 
are also common with other oral tyrosine kinase inhibitors, such as sorafenib, and require a careful clinical man-
agement to both lessen patients’ discomfort and maintain compliance to treatment. As with other forms of skin 
toxicities, in the past few years several analyses have been published regarding the correlation between targeted 
agents inducing skin toxicity and outcome. In particular, both panitumumab and cetuximab have a characteris-
tically favorable response profile in patients experiencing severe skin rash21–23. Recently, a study on the potential 
correlation between favorable outcome and the occurrence of HFSR in patients with HCC treated with sorafenib13 
has been published. Similarly to our findings, patients experiencing grade ≥ 2 skin toxicity with sorafenib therapy 
had the greatest probability of achieving an improved disease control. Granito et al.12 also recently published an 
extensive review on the prognostic role of different toxicities on outcome for patients with HCC treated with 
sorafenib. Interestingly, the occurrence of HFSR with sorafenib was one of the factors more frequently correlated 
with improved survival. In our analysis, however, skin rash was significantly correlated with improved overall 
survival and progression free survival, whereas only a not statistically significant trend was observed for HFSR. 
This discrepancy might be at least in part related to the increased use of prophylactic measures to counteract this 
frequent and unpleasant side effect. In fact, most patients treated pre-emptively usually experience less severe 
grades of HFSR and usually not as early as untreated patients.
Our analysis suggested that other relevant off-target effects (such as diarrhea and hypothyroidism) might cor-
relate to clinical activity in patients treated with regorafenib. Although to date this is the first analysis showing a 
potential correlation between the onset of these forms of side effects and regorafenib efficacy, a similar correlation 
can be observed once again in HCC patients receiving sorafenib. In particular, Di Costanzo et al.24 recently pub-
lished results of a cohort analysis comparing the outcome of patients who experienced these forms of toxicities 
while on treatment and those who experienced the same “side-effects” prior to treatment. The Authors found 
that, only in the population of patients on treatment, the occurrence of diarrhea and hypertension were related 
to improved survival. On the other hand, hypothyroidism results were in line with previous observations of renal 
cell carcinoma patients receiving sunitinib.
Figure 6. Median PFS stratified on the basis of having 0 ( ), 1 ( ), 2 ( ) or 3 ( ) side-effects 
related to Regorafenib treatment. Median PFS were respectively 2.25 vs 3.60 vs 5.63 vs 4.32 months, p of the 
whole group < 0.0001).
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Sample size limitations, the absence of a control group and the retrospective nature of our analysis prevent us 
from drawing definitive conclusions about the role of off-target effects correlated with clinical outcome during 
treatment with regorafenib, but at least our paper is able to confirm the fact that, if managed properly, toxicity 
from regorafenib-based therapy should not be viewed like a factor that should discourage medical oncologists in 
prescribing and continuing treatment. In our analysis only skin rash was independently correlated with both PFS 
and OS, whereas hypertension and diarrhea independently correlated with PFS and hypothyroidism correlated 
with OS. Strange as it may seem, these effects (particularly diarrhea, skin rash and hypothyroidism) seem to point 
out at some mechanism of action that, differently from what you would expect from an antiangiogenic drug, 
seems focused on the immune system.
Even though it should be tested in further analyses, that might be an intriguing field of further development: 
indeed, among its many targets, regorafenib also binds (and should block) both RET and KIT. These two targets 
are particularly well-known proto-oncogenes, with a correlation with different types of cancers such as the thy-
roid carcinomas for the former (and that might explain why hypothyroidism occurs) while the latter is involved 
in the pathogenesis of a series of different human cancers and in processes of hemopoiesis, T cell differentiation 
and lymphoid progenitor cell differentiation (and that might explain why the hypothesized auto-immune-like 
mechanism). It is then with some concern that suggestions25 regarding a potential usefulness in managing toxic-
ities from regorafenib-based therapy with the use of corticosteroids, based on this hypothesis, should be advised, 
that is due the potential immunodepressant activity of corticosteroids.
This factor might explain why, also in regorafenib treated patients, lymphocyte count and 
neutrophile-to-lymphocyte ratio9 might have a potential predictive role, as in highlighting the situations where 
immune system is more “receptive” to respond to this therapy.
These observations, if confirmed in larger, possibly prospective series of regorafenib-treated colorectal cancer 
patients, seem to imply that the identification of some reliable clinical factors such as severe skin rash, diarrhea 
and hypothyroidism may on the one hand be an early indicator of anti-tumour activity and on the other hand this 
could lead to an accurate toxicity management aimed at proper symptoms control rather than treatment definitive 
interruptions26. We are currently in the process of designing a trial based upon evaluation of molecular markers 
that might be relevant to regorafenib methabolism and ultimately might have a role in increasing the toxicity 
profile of this drug, as to allow a more careful selection of patients where these relevant side effects (diarrhea, 
hypothyroidism, skin rash) might be considered as surrogates for susceptibility to this drug.
When the balance between toxicity and efficacy is particularly relevant for treatment decision as with 
regorafenib for metastatic colorectal cancer, patients’ selection becomes crucial9. In this setting the possibility to 
further identify different risk-groups in metastatic colorectal cancer patients represents in fact a key-challenge for 
the treatment of this disease, particularly now that different options are available and many more are hopefully 
likely to come.
Methods
Patients Selection. All consecutive histologically-proven metastatic colorectal cancer patients, previously 
treated with standard treatment regimens (oxaliplatin, irinotecan, fluoropyrimidines, bevacizumab and either 
cetuximab or panitumumab in case of RAS, wild type status) receiving regorafenib monotherapy as per Italian 
label were eligible for our analysis: in particular, patients included should have received at least 2 prior chemo-
therapy regimens for metastatic disease, be in a relatively good (ECOG PS: 0–2) performance status, not have 
any contraindications to regorafenib monotherapy as in the case of active bleeding wounds, uncontrolled high 
blood pressure or history of recent heart failure or have already received regorafenib in previous lines of treat-
ment. We also included, due to the nature of the analysis, only all those patients who were adequately assessed 
for regorafenib-based toxicities, while patients where this kind of evaluation was not performed were excluded 
(it should be noted that no patient under regorafenib treatment was excluded due to the fact that, in Italy, toxicity 
assessment for regorafenib use is needed to prescribe and administer the drug to a patient).
All patients started treatment with regorafenib at the dose of 160 mg/day (day 1 to 21 each 28-day cycle), dose 
reductions were applied as clinically indicated. Tumour response was evaluated every 8 weeks by clinicians in 
accordance to the response evaluation criteria for solid tumours (RECIST version 1.1). Toxicity profile was graded 
accordingly to the NCI CTCAE criteria (Version 4.0) for all istances where it was possible. In particular, toxicities 
that were assessed by means of analysis were:
Hand-foot skin reaction (HFSR): patients were considered positive if they developed HFSR greater than or 
equal to NCI CTCAE grade II, with skin changes and toxicity interfering with ADL.
Skin rash: patients were considered positive if they developed maculopapular rash of intensity greater than or 
equal to NCI CTCAE grade II, covering 10–30% BSA or more.
Hypertension: patients were considered positive if they developed hypertension greater than or equal to NCI 
CTCAE grade II, with rounded up values of systolic pressure greater than 150 mmHg and/or values of diastolic 
pressure greater than 95 mmHg.
Diarrhea: patients were considered positive if they experienced at least one episode of diarrhoea greater than 
or equal to NCI CTCAE grade II. Also patients who experienced for at least one week during regorafenib intake 
continued diarrhoea equal in grade to NCI CTCAE grade I were considered positive.
AST/ALT increase: patients were considered positive if they experienced increase in AST/ALT, performed 
after 4 and after 8 weeks of treatment with regorafenib, greater than or equal to NCI CTCAE grade II, with 
increase in the range or greater than 3–5 times ULN for the laboratory that performs testing.
Bilirubin increase: patients were considered positive if they experienced increase in bilirubin levels, performed 
after 4 and after 8 weeks of treatment with regorafenib, greater than or equal to NCI CTCAE grade II, with 
increase in the range or greater than 1.5–3 times ULN for the laboratory that performs testing.
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Hypothyroidism: patients were considered positive if they experienced at least one of the following blood 
tests alterations performed after 4 and after 8 weeks of treatment with regorafenib, greater than or equal to NCI 
CTCAE grade I for hypothyroidism. In particular, patients with symptoms of hypothyroidism or even with sub-
clinical hypothyroism that showed increase in TSH levels greater or equal to 2 ULN and/or decrease of fT3/fT4 
levels less or equal to 0.5 LLN were considered positive.
Data Management and statistical Analysis. On the basis of previously published reports we hypoth-
esized that at least 20% of metastatic colorectal cancer patients would experience mild to severe (≥ G2 NCI 
CTCAE) toxicities during regorafenib. Assuming a 75% 6-month OS rate for the group of patients experiencing 
“severe” (> NCI CTCAE G2) toxicities and a 40% 6-month OS rate for the remaining patients, with α = 0.05 and 
β = 0.10, 140 patients were needed to confirm our hypothesis (28 patients with ≥ G2 NCI CTCAE toxicities and 
112 in the remaining group). Statistical analysis was performed with MedCalc Statistical Software version 14.10.2 
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2014). The association between categorical 
variables was estimated by Fisher’s exact test for categorical binomial variables or by chi-square test when indi-
cated. Survival probability over time was estimated by the Kaplan–Meier method. Significant differences in the 
probability of survival between the strata were evaluated by log-rank test. Cox’s multiple regression analysis was 
used to assess the role of off-target effects as predictive factors for clinical outcome adjusted for those variables 
that resulted significant at univariate analysis. The Holm-Sidak correction was used to adjust the values for mul-
tiple comparisons. Tested variables included hand-foot skin reaction (HFSR), skin rash, hypertension, diarrhea, 
fatigue, serum AST/ALT increase, serum bilirubin increase, hypothyroidism. All toxicities were graded as stated 
before. Other variables analysed were gender (male vs female), median age (< 70 vs ≥ 70 years), RAS status (wild 
type vs mutant), ECOG performance status (0 vs ≥ 1), previous lines for metastatic disease (≤ 3 vs ≥ 4). For statis-
tical analysis, overall survival (OS) was defined as the time interval between the treatment with regorafenib start 
date and death or last follow-up visit for patients lost at follow-up, whereas progression-free survival (PFS) was 
defined as the interval between the treatment with regorafenib start date and death, first sign of clinical progres-
sion or last follow-up visit for patients lost at follow-up. Disease control rate (DCR) was defined as the sum of 
the rate of achieving partial or complete response and the rate of patients who obtained stable disease at the first 
radiological evaluation.
Ethics. The study was performed in accordance with the protocol, all experimental protocols were approved 
by the Ethical Committee of the Azienda Ospedaliera Universitaria of Ancona, Italy, written informed consent 
was obtained for all patients enrolled into the analysis and methods were carried out in accordance with the 
approved guidelines.
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